Connect with us

NEWATLAS

Positive early data from large Phase 3 COVID-19 antibody trial

Avatar

Published

on

Pharmaceutical company Eli Lilly has announced its experimental antibody treatment can reduce a person’s risk of contracting COVID-19 by up to 80 percent. These preliminary results, from an ongoing Phase 3 trial, suggest the treatment may be an effective way to rapidly tamp down coronavirus outbreaks in unvaccinated communities.

Unlike a vaccine, which teaches the body to produce its own antibodies against a virus and can take weeks to generate effective immunity, monoclonal antibody treatment involves directly infusing large volumes of lab-produced antibodies into a patient.

In October last year Donald Trump touted the efficacy of antibody treatments after he received an experimental COVID-19 antibody cocktail produced by pharmaceutical company Regeneron. The next month Eli Lilly’s antibody treatment, called bamlanivimab, was granted Emergency Use Authorization by the US Food and Drug Administration (FDA).

With clinical trials still ongoing researchers are working to understand the optimal way to administer these kinds of antibody treatments. When the FDA granted bamlanivimab emergency authorization last year it was clear to note the approval was very limited to patients at the earliest stage of COVID-19. In fact, trials have indicated these treatments can worsen a patient’s condition if administered in later stages of the disease.

So all signs have suggested bamlanivimab, and other monoclonal antibody treatments, are probably most effective when administered to newly infected patients, or as a preventative agent for those in high-risk environments. Eli Lilly’s new announcement is reporting some data from a unique Phase 3 trial investigating whether bamlanivimab prevents COVID-19 infections in nursing homes or assisted care facilities.

The ongoing trial, which began in August, identified nursing home COVID-19 outbreaks and rapidly dispatched teams to administer infusions of either bamlanivimab or placebo to staff and patients within seven days of the first case being reported. The results recently announced by Eli Lilly claim those residents receiving bamlanivimab were up to 80 percent less likely to contract COVID-19 compared to residents in the same facility given a placebo.

“The results of this innovative study further support the belief that bamlanivimab – and potentially other monoclonal antibodies – can reduce symptoms and may even prevent COVID-19,” says Myron Cohen, co-principal investigator on the trial. “The antiviral activity seen with bamlanivimab treatment emphasizes the importance of early intervention to help counter the devastating impact the virus has had in this vulnerable population and other high-risk patients.”

As the trial is still ongoing these results have yet to be published in a peer-reviewed journal, so it is difficult to evaluate exactly how best these monoclonal antibody treatments can be used. Experts not affiliated with the research are cautiously optimistic, suggesting these findings are good news.

“The investigation reports a very significant impact – reducing both symptomatic disease and deaths,” says Daniel Altman, from Imperial College London. “This is a big result when one considers the massively disproportionate disease burden and fatalities around the world in care-homes. Earlier results in severe patients in a hospital setting had been disappointing, perhaps reflecting the point that at that later stage of disease, other disease processes are implicated, rather than just virus entry.”

Considering vaccines are currently being rolled out it is fair to ask what particular role these kinds of antibody treatments will have in the greater fight against COVID-19. Daniel Skovronsky, chief scientific officer at Eli Lilly, suggests bamlanivimab offers doctors a valuable tool that could help quash acute outbreaks, particularly in unvaccinated or high-risk populations.

“Of course, I think the vaccines are more effective than prophylaxis and likely longer lasting,” says Skovronsky. “So this should not be seen in any way as competition to vaccines. It should be for when it’s too late, when there’s an outbreak and people are getting exposed and there’s not going to be time for a vaccine to work.”

Source: Eli Lilly

Source: https://newatlas.com/health-wellbeing/coronavirus-antibody-eli-lilly-phase3-data/

NEWATLAS

Hidden Egyptian handbook reveals secrets of mummification

Avatar

Published

on

A recently discovered text written around 1450 BCE contains previously unknown details about Egyptian mummification process

A 3,500-year-old Egyptian medical text is shedding new light on the ancient practice of mummification. Recently discovered inside a much larger work, the papyrus document being studied by University of Copenhagen Egyptologist Sofie Schiødt is the oldest known mummification manual.

Continue Reading

Category: Science

Tags: University of Copenhagen, Mummies, Archaeology

Source: https://newatlas.com/science/egypt-mummification-manual-louvre-carlsberg-copenhagen/

Continue Reading

NEWATLAS

Lasers and plasma shockwaves used to measure ripeness of fruit

Avatar

Published

on

Researchers in Japan have developed a contactless way to measure the ripeness of soft fruit like mangoes

Judging how ripe a piece of fruit is can be a frustrating process for everyone from farmers to shoppers. Now, researchers at Shibaura Institute of Technology (SIT) in Japan have developed a new high-tech way to check, without touching or damaging soft fruit like mangoes. All it takes is a laser and some plasma shockwaves.

Continue Reading

Category: Science

Tags: Food, Fruit, Laser, Food technology

Source: https://newatlas.com/science/fruit-ripe-lasers-plasma-shockwaves/

Continue Reading

NEWATLAS

Broadcasting tech swaps stadium ads for regional advertising

Avatar

Published

on

Examples of the system showing two different ads (A,B) along with the magenta screen (C) which neither stadium audiences nor TV viewers see

When viewing sports coverage from other countries, it’s common to see sideline advertising boards that are promoting products you’ve never even heard of. This new TV system is capable of digitally replacing the content of those boards, so they’re advertising region-specific products.

Continue Reading

Category: Good Thinking, Lifestyle

Tags: Fraunhofer, Sports, Advertising, Broadcast, Television

Source: https://newatlas.com/good-thinking/fraunhofer-vibotec-sports-advertising/

Continue Reading

NEWATLAS

Scientists calculate life expectancy of Earth’s atmospheric oxygen

Avatar

Published

on

An artist's interpretation of the atmosphere of Archean Earth, prior to 2.4 billion years ago. A new study suggests it may return to this oxygen-poor, methane-rich atmosphere in about 1 billion years' time

The Earth has an expiry date – in about five billion years, the Sun will expand and swallow up our home world. But it turns out life on Earth could have a much earlier end point. A new study has found that in about a billion years’ time, the atmosphere will lose most of its oxygen rapidly, which may have important implications in the search for life on other planets.

Continue Reading

Category: Environment, Science

Tags: Oxygen, Atmosphere, Earth, Geology, Exoplanet, Extraterrestrial

Source: https://newatlas.com/environment/earth-atmosphere-oxygen-life-expectancy/

Continue Reading
Blockchain5 days ago

‘Bitcoin Senator’ Lummis Optimistic About Crypto Tax Reform

Blockchain5 days ago

Dogecoin becomes the most popular cryptocurrency

Blockchain5 days ago

Billionaire Hedge Fund Manager and a Former CFTC Chairman Reportedly Invested in Crypto Firm

Blockchain5 days ago

Bitcoin Price Analysis: Back Above $50K, But Facing Huge Resistance Now

Blockchain5 days ago

Institutional Investors Continue to Buy Bitcoin as Price Tops $50K: Report

Blockchain5 days ago

NEXT Chain: New Generation Blockchain With Eyes on the DeFi Industry

Big Data3 days ago

Online learning platform Coursera files for U.S. IPO

Blockchain4 days ago

Elrond & Reef Finance Team Up for Greater Connectivity & Liquidity

Blockchain4 days ago

Here’s why Bitcoin could be heading towards $45,000

Blockchain4 days ago

SushiSwap Goes Multi-Chain after Fantom Deployment

Blockchain4 days ago

Non-Fungible Tokens – NFT 101 – Why People are Spending Millions of Dollars for Crypto Art and Digital Items

Blockchain5 days ago

UK Budget Avoids Tax Hikes for Bitcoin Gains

Blockchain4 days ago

eToro and DS TECHEETAH Change Face of Sponsorship With Profit-Only Deal

Blockchain4 days ago

Apple Pay Users Can Now Buy COTI Via Simplex

Blockchain4 days ago

TomoChain (TOMO) Increases after Retesting Previous All-Time High

Blockchain5 days ago

Ethereum’s price prospects: What you need to know

Business Insider2 days ago

Wall Street people moves of the week: Here’s our rundown of promotions, exits, and hires at firms like Goldman Sachs, JPMorgan, and Third Point

Blockchain5 days ago

Silicon Valley-based Taraxa Unveils Details of Upcoming Public Sale

Blockchain4 days ago

Tron Dapps Market Gets A Boost As Bridge Oracle All Set to Launch MainNet Soon

Blockchain5 days ago

Drug traffickers ‘increasingly’ used Bitcoin ATMs to aid illicit transfers in 2020

Trending